Icrf 198

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 591206

CAS#: 75459-34-6

Description: Icrf 198 is a biochemical.


Chemical Structure

img
Icrf 198
CAS# 75459-34-6

Theoretical Analysis

MedKoo Cat#: 591206
Name: Icrf 198
CAS#: 75459-34-6
Chemical Formula: C11H20N4O6
Exact Mass: 304.1383
Molecular Weight: 307.3
Elemental Analysis: C, 43.42; H, 6.62; N, 18.41; O, 31.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Icrf 198; Icrf-198; Icrf198;

IUPAC/Chemical Name: Glycine, N,N'-(1-methyl-1,2-ethanediyl)bis(N-(2-amino-2-oxoethyl)-

InChi Key: YXWHFCSUHVBWFG-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H20N4O6/c1-7(15(4-9(13)17)6-11(20)21)2-14(3-8(12)16)5-10(18)19/h7H,2-6H2,1H3,(H2,12,16)(H2,13,17)(H,18,19)(H,20,21)

SMILES Code: CC(N(CC(N)=O)CC(O)=O)CN(CC(N)=O)CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 307.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tycova A, Vido M, Kovarikova P, Foret F. Interface-free capillary electrophoresis-mass spectrometry system with nanospray ionization-Analysis of dexrazoxane in blood plasma. J Chromatogr A. 2016 Sep 30;1466:173-9. doi: 10.1016/j.chroma.2016.08.042. Epub 2016 Aug 23. PubMed PMID: 27613146.

2: Kovarikova P, Pasakova-Vrbatova I, Vavrova A, Stariat J, Klimes J, Simunek T. Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium. J Pharm Biomed Anal. 2013 Mar 25;76:243-51. doi: 10.1016/j.jpba.2012.12.024. Epub 2012 Dec 28. PubMed PMID: 23339990.

3: Kovaříková P, Stariat J, Klimeš J, Hrušková K, Vávrová K. Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites--the cardioprotectant dexrazoxane as a model case. J Chromatogr A. 2011 Jan 21;1218(3):416-26. doi: 10.1016/j.chroma.2010.11.050. Epub 2010 Nov 27. PubMed PMID: 21168142.

4: Hasinoff BB, Patel D. The iron chelator Dp44mT does not protect myocytes against doxorubicin. J Inorg Biochem. 2009 Jul;103(7):1093-101. doi: 10.1016/j.jinorgbio.2009.05.007. Epub 2009 May 21. PubMed PMID: 19535146.

5: Schroeder PE, Hasinoff BB. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat. Drug Metab Dispos. 2005 Sep;33(9):1367-72. Epub 2005 Jun 24. PubMed PMID: 15980099.

6: Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol. 2003 Aug;52(2):167-74. Epub 2003 May 15. PubMed PMID: 12750840.

7: Schroeder PE, Hasinoff BB. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother Pharmacol. 2002 Dec;50(6):509-13. Epub 2002 Oct 31. PubMed PMID: 12451479.

8: Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc Toxicol. 2002;2(2):111-8. PubMed PMID: 12271154.

9: Lopez M. [Development of cancer chemotherapy. Cytoprotective agents]. Clin Ter. 2001 Mar-Apr;152(2):135-43. Review. Italian. PubMed PMID: 11441524.

10: Vaidyanathan S, Boroujerdi M. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. Cancer Chemother Pharmacol. 2000;46(2):93-100. PubMed PMID: 10972478.

11: Loyevsky M, Sacci JB Jr, Boehme P, Weglicki W, John C, Gordeuk VR. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PubMed PMID: 9990337.

12: Hochster HS. Clinical pharmacology of dexrazoxane. Semin Oncol. 1998 Aug;25(4 Suppl 10):37-42. Review. PubMed PMID: 9768822.

13: Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, Yalowich JC. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol. 1997 Jun 15;53(12):1843-53. PubMed PMID: 9256159.

14: Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR Jr, Ferrans VJ. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother Pharmacol. 1997;40(5):400-8. PubMed PMID: 9272116.

15: Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, Ferrans VJ. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology. 1995 Apr 12;98(1-3):163-75. PubMed PMID: 7537925.

16: Hasinoff BB. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane). Free Radic Res. 1995 Apr;22(4):319-25. PubMed PMID: 7633562.

17: Malisza KL, Hasinoff BB. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Arch Biochem Biophys. 1995 Feb 1;316(2):680-8. PubMed PMID: 7864623.

18: Hüsken BC, de Jong J, Beekman B, Onderwater RC, van der Vijgh WJ, Bast A. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother Pharmacol. 1995;37(1-2):55-62. PubMed PMID: 7497597.

19: Thomas C, Carr AC, Winterbourn CC. Free radical inactivation of rabbit muscle creatinine kinase: catalysis by physiological and hydrolyzed ICRF-187 (ICRF-198) iron chelates. Free Radic Res. 1994 Nov-Dec;21(6):387-97. Erratum in: Free Radic Res 1995 May;22(5):483. PubMed PMID: 7834053.

20: Hasinoff BB. Quantitation of the dexrazoxane hydrolysis product ADR-925 by fluorescence detection of its terbium(III) complex after high-performance liquid chromatographic separation. J Chromatogr B Biomed Appl. 1994 Jun 17;656(2):451-5. PubMed PMID: 7987502.